AGENTS THAT AFFECT BONE MINERAL HOMEOSTASIS

: Dr Shaikh Fahad Falah

Lecture Objectives

-Classify Drugs Used in Metabolic Bone Disorders

- -Enlist Calcium Preparations
- -Enlist Vitamin D Preparations
- -Clinical Uses of Calcium and Vitamin D
- -Describe Actions of Vitamin D on Intestine, Kidney and Bone
- -Describe the Mechanism of Actions, Clinical Uses, and Adverse Effects of Bisphosphonates
- -Describe the Mechanism of Action, Clinical Uses and Adverse Effects of Calcitonin
- -Classify Drugs Used to Treat Osteoporosis
- -Explain the Mechanism of Actions of SERM (Raloxifene) selective estrogen receptor modulator and RANK Ligand (Denosumab) Receptor activator of nuclear factor-kB

Introduction

- Calcium and phosphate are the major mineral constituents of bone and their homeostatic balance is carefully maintained.
- Approximately 98% of the 1-2 kg of calcium and 85% of the 1 kg of phosphorus in the human adult are found in bone, the principal reservoir for these minerals.
- Calcium and phosphate enter the body from the intestine.
- In the steady state, renal excretion of calcium and phosphate balances intestinal absorption. In general, over 98% of filtered calcium and 85% of filtered phosphate is reabsorbed

PTH and the steroid vitamin D principally regulate calcium and phosphate homeostasis.

- Vitamin D is a prohormone rather than a true hormone
- PTH stimulates the production of the active metabolite of vitamin D, 1,25(OH)2D.

- 1,25(OH)2D, on the other hand, suppresses the production of PTH.
- 1,25(OH)2D stimulates the intestinal absorption of calcium and phosphate.
- 1,25(OH)2D and PTH promote both bone formation and resorption in part by stimulating the proliferation and differentiation of osteoblasts and osteoclasts.
- Both PTH and 1,25(OH)2D enhance renal retention of calcium, but PTH promotes renal phosphate excretion.


Bone remodelling

- Bone remodeling is a dynamic, lifelong process in which old bone is removed from the skeleton and new bone is added.
- It consists of two distinct stages resorption and formation involves osteoblasts and osteoclast.
- □ Usually, the removal and formation of bone are in balance and maintain skeletal strength and integrity.

Osteoblasts are responsible for bone matrix synthesis. They secrete a collagen rich ground substance essential for mineralization.

- The osteoblasts also have estrogen receptors. Estrogens can actually increase the number of osteoblasts, increasing therefore collagen production
- **Osteoclasts** play a role in controlling the extracellular concentration of calcium and phosphate, and are directly stimulated by calcitonin and inhibited by PTH .

Sites of calcium regulation



- If the plasma calcium levels become **elevated**, soft tissue calcification may occur; there may be decreased excitability of nervous tissue and muscle weakness, lethargy and coma.
- If plasma calcium levels become **reduced**, there may be paresthesia and in more severe cases, tetany and convulsions.

Calcium preparations

calcium carbonate(40%) calcium citrate calcium gluconate calcium lactate calcium chloride



Indigestion(antacid) Hyperkalemia Hypocalcemia Kidney Failure Osteoporosis

Drugs used in Bone mineral homeostasis

A. Hormonal regulators

Parathyroid hormone
Vitamin D
Calcitonin
Glucocorticoids
Estrogens

B. Non hormonal regulators
Bisphosphonates
Calcimimetics
Plicamycin
Thiazides
Fluoride

A. Hormonal agents

1.Parathyroid hormone (PTH)

Example: Teriparatide inj

- Parathyroid hormone is a peptide hormone composed of 84 amino acids
- The major role for PTH is the maintenance of normal extracellular calcium levels
- Stimulates intestinal absorption
- Decrease urinary excretion of calcium
- Mobilize bone to provide calcium.

Pharmacokinetics

- Given SC or IV once daily
- Peak concentration occurs after 30min
- Half life is 10 min after IV injection and 1 hour after SC injection.

Uses

- Anabolic effect on bone: increase in bone density, decrease in fractures
- Treatment of severe osteoporosis: when initial therapy with anti resorptive drug has not been effective

Side effects

□Nausea, dizziness, headache, arthalgias

Mild hypercalcaemia, transient orthostatic hypotensionLeg cramps

Vitamin D Preparations

Ergocalciferol{vitamin D2}

Cholecalciferol(vitamin D3)

Calcitriol


Alfacalcidol

Calcipotriol

2. Vitamin D

- **Example**: Calcitriol, Cholecalciferol.
- Vitamin D is produced in the skin from 7-dehydrocholesterol under the influence of ultraviolet irradiation.
- Vitamin D is a prohormone that serves as precursor to a number of biologically active metabolites. It is first hydroxylated in the liver to form 25-hydroxyvitamin D (25[OH]D).
- This metabolite is further converted in the kidney to a number of other forms, the best-studied of which are 1,25-dihydroxyvitamin D (1,25[OH]2D) and 24,25-dihydroxyvitamin D (24,25[OH]2D).
- Only vitamin D and 1,25(OH)2D (as calcitriol) are available for clinical use.

Mechanisms of Action of 1,25-dihydroxy vitamin D



© Elsevier 2005. Minneman & Wecker: Brody's Human Pharmacology 4e www.studentconsult.com

- •1,25-dihydroxyvitamin D increases calcium and phosphate absorption from the intestine; increasing serum concentrations
- The ions deposit in bone, increasing bone mineralization

MoA

- GI tract:Increased calcium and phosphate absorption by 1,25 (OH)2D.
- **Bone**:Increased calcium and phosphate resorption and bone formation
- **Kidney**: decreases Calcium and phosphate excretion

Pharmacokinetics

- Given orally and bind to alpha protein in the blood.
- Half life is about 22hrs.
- Eliminated through faeces.

Uses:

- Prevention and treatment of rickets, osteoporosis, otseomalacia and vitamin D deficiency
- Hypocalcaemia
- Osteodystrophy of chronic renal failure, due to decrease calcitriol generation

Side effect

Exess intake causes hypercalcaemia manifested by constipation, depression, weakness and fatigue

□Polyuria and polydipsia

May lead to renal failure and kidney stones due to deposit of calcium salt in the kidney

3. Calcitonin

Examples: Calcitonin, salcatonin, procaine.

• The calcitonin is secreted by the parafollicular cells of the thyroid gland.it is a peptide hormone.

MoA

- The principal effects of calcitonin are to **lower** serum calcium and phosphate by actions on bone and kidney.
- Calcitonin inhibits osteoclastic bone resorption.(it slows dowen bone loss)
- In kidney it decreases the reabsorption of both calcium and phosphate in the proximal tubules.
- Secretion is always determined by calcium concentration.

Pharmacokinetics

- Given by SC or intranasal
- Plasma Half life is 4-12min
- □Action last for several hours

Uses:

- Hypercalcaemia associated with neoplasia
- □Pagets disease of bone
- Postmenopausal and corticosteriods induced osteoporosis

Side effects

- □Nausea and vomiting.
- □Facial flashing.
- □Tingling sensation in the hands.
- Unpleasant taste in the mouth.
- Local hypersensitivity.

4. Glucocorticoids

MOA

Excessive glucocorticoids hormones alter bone mineral homeostasis by antagonizing vitamin D-stimulated intestinal calcium transport, by stimulating renal calcium excretion, and by blocking bone formation.

inhibit cytokine release by cytolytic effects of some bone tumors, inhibit calcium absorption from intestine and by increasing calcium excretion in urine.

Uses

Hypercalcemia due to malignancies or Vitamin D intoxication

ESTROGEN

MoA

- Estrogens can prevent accelerated bone loss during the immediate postmenopausal period and at least transiently increase bone in the postmenopausal woman.
- Estrogens reduce the bone-resorbing action of PTH.
- Estrogen administration leads to an increased 1,25(OH)2D level in blood..
- Estrogen receptors have been found in bone, and estrogen has direct effects on bone remodeling.

Pharmacokinetics

- Well absorbed in Git
- Widely distributed in tissue and converted to an active metabolite in liver, lungs spleen , kidneys,
- Half life is 32 hrs
- Excretion in feaces

Uses:

- Hormone replacement therapy
- Prevention and treatment of postmenoupasal osteoporosis

Side effects

- □Hot flashes and leg cramps
- □May cause venous thromboembolism

B. Non Hormonal agents

1. Bisphosphonates

Examples:Etidronate, pamidronate(only parentral), alendronate, ibandronate, zolendronate

MoA (*inhibition of osteoclast activity*)

- Decrease activity of the osteoclast proton pump (needed to dissolve hydroxyapatite) and increases osteoclast apoptosis ("programmed cell death").
- BPs also reduces transformation of osteoclast precursor cells to mature osteoclasts.
- □Bind to bone, inhibit calcium resorption

They also interfere with mevalonate pathway of cholesterol synthesis which is required for normal function of osteoclasts.

Pharmacokinetics

- Given orally and poorly absorbed, may be given IV in malignancy.
- □50% of dose accumulates at site of bone mineralization. Free drug excreted by kidneys
- Take on empty stomach, with water, 30 minutes before other intake

Side effects:

- GIT disturbance, (esophagitis, gastritis)
- Peptic ulcer disease
- □bone pain
- osteomalacia

Uses:

- □Treatment of osteoporosis
- Treatment of Paget's disease of bone
- Treatment of hypercalcemia of malignancy
 - Osteolytic bone metastasis

2. Calcimimetics

Examples:Cinacalcet

MoA

- Enhances the sensitivity of the parathyroid calcium sensing receptors to the concentration of blood calcium;
- □–Make it more responsive to calcium
- □– Suppress PTH
- □ Can decrease serum calcium and phosphate

3. Plicamycin

MoA

- Plicamycin is a cytotoxic(anti tumor) antibiotic .it produces its anticancer effects by binding to DNA and inhibiting the production of proteins necessary for sustaining the life of a cell
- Inhibits osteoclast activity,(it inhibits RNA synthesis in osteoclasts)


Preventing bone breakdown

Uses

- Treat hypercalcemia
- Treat pagets disease

4. Thiazides MOA

- The principal application of thiazides in the treatment of bone
- mineral disorders is in reducing renal calcium excretion. By increasing calcium reabsorption from the luminal membrane into the interstitium in exchange for sodium, thiazides reduce urine calcium levels and increase blood calcium.
- However, if indicated, this effect of thiazide diuretics makes thiazides useful for nephrolithiasis and osteoporosis treatment



5. Fluoride

MoA

- Stimulate osteoblast activity and increase bone formation
- □Increases bone density
- Fluoride use increases incidence of fractures because of weaker bone formation

Side effects
GI side effects: Nausea
Musculoskeletal pain, joint swelling
Increased risk of fracture: Dose-related

Phosphate Binders

- These are medications that bind phosphate in the gut to prevent absorption, used in combination with calcium supplements to treat hyperphosphatemia (renal failure, hypoparathyroidism,vit D intoxication)
- High phosphate leads to elevated PTH
- High phosphate causes decreased vitamin D levels and hypocalcemia
- Should be given with meals, Include;
- Sevelemar (Renagel)
- Fosrenol (lanthanum carbonate)

Side effects

- GI discomfort
- □Mild metabolic acidosis
- Uses
- Secondary hyperparathyroidism

Drugs For Osteoporosis

- 1. Calcitriol
- 2. Bisphosphonates
- 3. Cinacalcet
- 4. Calcitonin
- 5. Estrogen
- 6. Calcium
- 7. PTH

Denosumab(RANKL)

(INHIBITOR) Receptor activator of nuclear factor-kB ligands. It is a human monoclonal antibody that binds RANKL, preventing RANKL from activiting RANKL, its receptor on the osteoclast surface. With reduse RANK-RANKL binding, osteoclast formation, function and survival are inhabited, so bone resorption decreases and bone mass increases.

Uses;

Osteoporosis

Treatment induced bone loss

Metastases to bone

Giant cell tumor of bone

Raloxifene. SERM . selective estrogen receptor modulator

- The MOA of raloxifene occurs through binding to estrogen receptors. estrogen-agonistic effect on bone.

-During reproductive life in the female, estrogens have an important role in maintenance of bone integrity. Inhibit the cytokines that recruit osteoclast, and oppose the boneresorbing calcium mobilising action of PTH.

Thank You